CD-Laboratory for Activation of Immunogenic Cell Death in Lung Cancer

Despite major advances in personalized medicine, lung cancer remains the leading cause of cancer-related deaths worldwide and thus poses a major medical challenge. In light of the urgent need for innovative therapeutic approaches, a new Christian Doppler Laboratory has been established at the Medical University of Graz, dedicated to developing novel therapies for lung cancer. The seven-year program focuses on non-small cell lung cancer (NSCLC) and explores innovative ways to trigger immunogenic cell death, thereby helping the immune system to recognize and attack tumors more efficiently. The CD Laboratory is funded by the Federal Ministry of Economy, Energy, and Tourism (BMWET) and the industry partner Boehringer Ingelheim.